This item is in: Biomedicine > Intellectual property, regulation
Patent litigation in the pharmaceutical and biotechnology industriesG E Morgan, Winston & Strawn LLP, UK
Woodhead Publishing Series in Biomedicine No. 26
- provides in-house counsel with a guide to strategic multi-jurisdictional litigation within the pharmaceutical and biotechnology industries
- highlights how best to integrate the patent and medicinal regulatory aspects of product development and lifecycle management
- provides institutional investors with an insight into the unique considerations behind enforcing intellectual property in the pharmaceutical and biotechnology fields
- reviews recent developments concerning the patentability and enforceability of biotechnology patents, both in the EU and US
- provides insight and opinion regarding the future of patent litigation in the EU
Written by a leading practitioner in the field, Patent litigation in the pharmaceutical and biotechnology industries focuses on the key subject of multi-jurisdictional patent litigation strategies and product lifecycle management in the pharmaceutical and biotechnology industries. This book therefore looks at the characteristics and strategies typically employed in fighting multi-jurisdictional litigation within these industries. In particular, patentability and the enforceability of biotechnological inventions are examined as they remain one of the most fluid, commercially important and emotive topics in the patent industry.
The book reviews the current position as regards these issues in the biotechnology industries and reports on likely key developments: such as the US gene patent litigation brought to block gene patents in principle and also the reference currently pending before the Court of Justice in Europe that will determine the scope of protection provided under Article 9 Biotechnology Directive in relation to DNA-based patent claims.
ISBN 1 907568 20 4
ISBN-13: 978 1 907568 20 6
December 2014
270 pages 234 x 156mm hardback
Approx. £125.00 / US$210.00 / €150.00
Not yet published
 | An e-book version of this title will be available from
Woodhead Publishing Online. To view the current titles available visit Woodhead Publishing Online
|
About the author
Gareth E. Morgan studied Biochemistry at Jesus College, Oxford University, and obtained a degree with first class honours in 1991. He then studied for a D.Phil in molecular biology, focussing on the regulation of the gene for human clotting factor IX.
His legal studies were completed at BPP Law School in London and he qualified as a solicitor within the IP Department of Herbert Smith in 2000. He then moved to Taylor Wessing in 2005 and subsequently became a partner in the Patents Group in the London office in 2008. In 2010 he moved to DLA Piper to take up a role within the Intellectual Property and Technology Group, again in the firm's London office, specialising in patent-related matters and medicinal regulatory advice.
He qualified as a Solicitor Advocate in 2004 and is an Associate Member of both CIPA (the Chartered Institute of Patent Attorneys) and the UNION (European Union of Intellectual Property Practitioners). He is also a member of the AIPPI.
Titles which may also be of interest:
Biobanks
The impact of regulation on drug development
Contract research and manufacturing services (CRAMS) in India
Patently innovative
Quality assurance
Contents
Choosing your forum; Litigating in the US; Litigating in Europe; Litigating pharma patents; Litigating biotechnology patents; The US ITC regime; Medicinal regulatory considerations; Patent term extension and the SPC regime; A unified patent litigation system for Europe; Conclusions.